Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin/Metformin XR vs Synjardy XR in Healthy Subjects
NCT07694115Phase 1Completed
- Sponsor
- Humanis
- Start
- May 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 48 hours and Area under the curve from time 0 to last collection time at 48 hours. Started May 2026; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07694115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694115.